Maury Raycroft
Stock Analyst at Jefferies
(1.82)
# 3,329
Out of 5,090 analysts
55
Total ratings
35.71%
Success rate
-7.97%
Average return
Main Sectors:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintains: Buy | $108 → $134 | $105.63 | +26.86% | 2 | Dec 2, 2025 | |
| AUPH Aurinia Pharmaceuticals | Upgrades: Buy | $10 → $21 | $15.62 | +34.44% | 1 | Nov 7, 2025 | |
| OPK OPKO Health | Downgrades: Hold | $2 → $1.6 | $1.34 | +19.40% | 1 | Oct 31, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $550 → $549 | $458.12 | +19.84% | 4 | Oct 30, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Hold | $18 → $7 | $6.25 | +12.00% | 2 | Oct 17, 2025 | |
| KOD Kodiak Sciences | Initiates: Buy | $15 | $24.34 | -38.37% | 1 | Sep 22, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.11 | +65.88% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $10.24 | +417.58% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $5.53 | +44.67% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.50 | +504.96% | 1 | Dec 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.06 | +239.81% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $3.27 | +83.49% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $9.63 | +97.30% | 1 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $15 | $3.74 | +301.07% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $44.26 | -11.88% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.55 | +993.29% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.78 | +1,192.13% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $3.12 | +6,150.00% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.59 | +44.93% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $44.90 | -86.64% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $61.44 | +22.07% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $10.42 | +5.57% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $21.50 | +25.58% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.99 | +151.26% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $9.00 | +300.00% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $5.77 | +1,719.76% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $56.88 | +202.39% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.67 | +1,660.30% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $9.61 | +337.04% | 3 | Nov 1, 2017 |
Celcuity
Dec 2, 2025
Maintains: Buy
Price Target: $108 → $134
Current: $105.63
Upside: +26.86%
Aurinia Pharmaceuticals
Nov 7, 2025
Upgrades: Buy
Price Target: $10 → $21
Current: $15.62
Upside: +34.44%
OPKO Health
Oct 31, 2025
Downgrades: Hold
Price Target: $2 → $1.6
Current: $1.34
Upside: +19.40%
Alnylam Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $550 → $549
Current: $458.12
Upside: +19.84%
Kezar Life Sciences
Oct 17, 2025
Downgrades: Hold
Price Target: $18 → $7
Current: $6.25
Upside: +12.00%
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $24.34
Upside: -38.37%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.11
Upside: +65.88%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $10.24
Upside: +417.58%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $5.53
Upside: +44.67%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.50
Upside: +504.96%
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.06
Upside: +239.81%
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $3.27
Upside: +83.49%
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $9.63
Upside: +97.30%
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $3.74
Upside: +301.07%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $44.26
Upside: -11.88%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.55
Upside: +993.29%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.78
Upside: +1,192.13%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $3.12
Upside: +6,150.00%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.59
Upside: +44.93%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $44.90
Upside: -86.64%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $61.44
Upside: +22.07%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $10.42
Upside: +5.57%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $21.50
Upside: +25.58%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.99
Upside: +151.26%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $9.00
Upside: +300.00%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $5.77
Upside: +1,719.76%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $56.88
Upside: +202.39%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.67
Upside: +1,660.30%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $9.61
Upside: +337.04%